

姓名	王琳	籍贯	山东威海	最后学历	博士	
最后毕业院校	中国药科大学		所学专业	药物代谢动力学		
研究生导师类别	专业学位硕士生导师		职称/职务	讲师		
办公电话			电子邮件	rushanwanglin@126.com		
个人学习及工作经历	<p>2008.09-2012.06, 中国药科大学, 药学, 学士;</p> <p>2012.09-2017.06 中国药科大学, 药物代谢动力学, 博士;</p> <p>2017.08-2019.12 烟台药物研究所, 工程师;</p> <p>2020.01-至今 烟台大学药学院, 讲师</p>					
学术兼职						
目前研究方向简介	<ol style="list-style-type: none"> 1. 药物代谢动力学 2. 代谢组学 3. 新药发现与筛选评价 					
近五年主持（或参与）教学、科研项目	<ol style="list-style-type: none"> 1. 烟台市科技创新发展计划, 2020MSGY057, 靶向 DPP-4 的新型降糖药物 LC-26 的药代-药效协同研究, 2020-01 至 2021-12, 结题, 主持 2. 中科环渤海（烟台）药物高等研究院, 自主部署科研项目, LX211011, 1 类新药 MDMX 小分子抑制剂的成药性研究, 2021-11 至 2024-10, 在研, 参与 3. 山东省科技厅, 山东省自然科学基金, ZR2021LSW011, 基于阻断 AHA1-HSP90 相互作用的 AHA1 小分子抑制剂的发现及其抗复发难治性多发性骨髓瘤研究, 2022-01 至 2024-12, 在研, 参与 					
近五年教学、科研获奖及专利						

<p>近五年已发表的代表性论著</p>	<ol style="list-style-type: none"> 1. Wang L, Lei H, Lu J, Wang W, Liu C, Wang Y, Yang Y, Tian J*, Zhang J*. Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS. <i>Molecules</i>. 2023, 10;28(6):2550. 2. Lin C¹, Kong Y¹, Wang F, Rong R, Li X, Xiao R, Wu Z, Zhang Q*, Wang L*. Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. <i>Bioorg Chem</i>. 2022, 123: 105767. 3. Wang L¹, Li X¹, Kong Y, Wang F, Zhang Q, Lin C*, Rong R*. Pharmacokinetics, tissue distribution and excretion of compound 6c, a novel DPP-4 inhibitor, following intragastric administration in rats by ultra-performance liquid chromatography-tandem mass spectrometry. <i>Eur J Pharm Sci</i>. 2022, 173:106162. 4. Wang L, Wang J, Lin C, Wang F, Li X, Liu W*. Simultaneous Quantification of Pioglitazone and Omarigliptin in Rat Plasma by UHPLC-MS/MS and Its Application to Pharmacokinetic Study after Coadministration of the Two Drugs. <i>J Anal Methods Chem</i>. 2021, 2021:6693366. 5. Lin C*, Li P, Wang L*. Visible-light induced Cross-Dehydrogenative-Coupling (CDC) reactions of N-aryl tetrahydroisoquinolines under aerobic conditions. <i>Tetrahedron Letters</i>, 2021, 73:153102 6. Wang L*; Li X; Kong Y; Zhang Q; Xie H*. Development of a sensitive UHPLC-MS/MS method for the pharmacokinetics study of a novel tyrosine kinase inhibitors, 1-[4-(4-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-phenyl)-piperazin-1-yl]-propanone in rats. <i>Biomedical Chromatography</i>, 2021, 35(5): e5059. 7. Sun S¹, Cheng D¹, Kong S, Li X, Li T, Yu Q, Wang L*. A rapid and sensitive method for quantification of ibrutinib in rat plasma by UPLC-ESI-MS/MS: validation and application to pharmacokinetic studies of a novel ibrutinib nanocrystalline. <i>Biomed Chromatogr</i>. 2020, 34(1): e4703. 8. Wang L¹, Ye H¹, Sun D, Meng T, Cao L, Wu M, Zhao M, Wang Y, Chen B, Xu X, Wang G*, Hao H*. Metabolic Pathway Extension Approach for Metabolomic Biomarker Identification. <i>Anal Chem</i>. 2017, 89(2):1229-1237. 9. Bai M, Wu M, Jiang M, He J, Deng X, Xu S, Fan J, Miao M, Wang T, Li Y, Yu X, Wang L, Zhang Y, Huang S, Yang L, Jia Z, Zhang A. LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease. <i>EMBO Mol Med</i>. 2023, 8;15(2): e16581. 10. Zhao M, Chen Q, Xu W, Wang H, Che Y, Wu M, Wang L, Cao L, Hao H. Total ginsenosides extract induce autophagic cell death in NSCLC cells through activation of endoplasmic reticulum stress. <i>J Ethnopharmacol</i>. 2019, 243:112093. 11. Wang Y¹, Liu Z¹, Lu J, Wang W, Wang L, Yang Y, Wang H, Ye L, Zhang J*, Tian J*. Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. <i>Front Pharmacol</i>. 2023, 21;14:1161964.
<p>指导研究生情况</p>	<p>博士：已毕业 名，在读 名。 硕士：已毕业 1 名，在读 2 名。</p>

